Cargando…

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial

INTRODUCTION: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merle, Philippe, Kudo, Masatoshi, Edeline, Julien, Bouattour, Mohamed, Cheng, Ann-Lii, Chan, Stephen L., Yau, Thomas, Garrido, Marcelo, Knox, Jennifer, Daniele, Bruno, Breder, Valeriy, Lim, Ho Yeong, Ogasawara, Sadahisa, Cattan, Stéphane, Chao, Yee, Siegel, Abby B., Martinez-Forero, Iván, Wei, Ziwen, Liu, Chih-Chin, Finn, Richard S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601873/ https://www.ncbi.nlm.nih.gov/pubmed/37901200 http://dx.doi.org/10.1159/000529636

Ejemplares similares

ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240
por: Vogel, Arndt, et al.
Publicado: (2021)

Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
por: Verset, Gontran, et al.
Publicado: (2022)

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
por: Llovet, Josep M., et al.
Publicado: (2022)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
por: Hamid, Omid, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
por: Jabbour, Salma K., et al.
Publicado: (2021)

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
por: Mateos, Maria-Victoria, et al.
Publicado: (2015)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
por: Qu, Jialin, et al.
Publicado: (2020)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
por: Zhan, Mei, et al.
Publicado: (2022)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
por: Si, Lu, et al.
Publicado: (2022)

Keynotes
Publicado: (2023)

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
por: Eggermont, Alexander M. M., et al.
Publicado: (2020)

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial
por: Elassaiss‐Schaap, J, et al.
Publicado: (2016)

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
por: Cohen, Roger B., et al.
Publicado: (2018)

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
por: Kang, S. P., et al.
Publicado: (2017)

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
por: O'Malley, David M., et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
por: Kojima, Takashi, et al.
Publicado: (2022)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
por: Hattori, Masaya, et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
por: Satake, Hironaga, et al.
Publicado: (2022)

Keynote Address
por: Zinsou, Lionel
Publicado: (2019)

Keynote Address
por: Cherkaoui El Moursli, Rajaa
Publicado: (2019)

Keynote Address
por: Schönenberger, Klaus
Publicado: (2019)

Welcome & Keynote
por: Martin, Robert "Uncle Bob"
Publicado: (2019)

Keynote Address
por: Bordry, Frederick
Publicado: (2019)

Keynote presentations
por: Desai, Nitin, et al.
Publicado: (2004)

Keynote Lectures
Publicado: (2004)

Keynote Lecture
Publicado: (2017)

KEYNOTE ADDRESS
por: Fenner, Frank
Publicado: (1986)

Keynote Symposium
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ks7qh6it062bhg8pqlvn07s1n